Newsroom | 5709 results

NASHVILLE, Tenn.--(BUSINESS WIRE)--Radiology Partners, Inc. (RP), through RP Clinical Services and its affiliated practices, today announced two leadership appointments, effective July 20. Matt Peterson has been named President of RP Clinical Services, reporting to Rich Whitney, Chairman and Chief Executive Officer of RP. Krishna Nallamshetty, MD, will become full-time Chief Operating Officer of RP Clinical Services after serving as Interim COO since December, and will also serve as Interim Chi...

NEWTON, Mass.--(BUSINESS WIRE)--Inflammasome Therapeutics' K8 slowed GA lesion growth 54% and showed a 4.0-letter vision advantage at six months in Phase 2. Phase 3 planned....

SALT LAKE CITY--(BUSINESS WIRE)--iVeena Delivery Systems, Inc., (“iVeena”) a clinical-stage ophthalmic biopharmaceutical company, today announced the successful completion of its Phase 1 clinical trial evaluating the safety of IVMED-85, an investigational, preservative-free ophthalmic solution being developed for the treatment of pediatric myopia. iVeena has completed the first-in-human, randomized, double-masked, vehicle-controlled Phase 1 study, which demonstrated a favorable safety profile a...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced strong preliminary net sales for the second quarter ended July 3, 2026. STAAR is announcing its preliminary net sales in advance of its quarterly earnings announcement, which it expects to issue on August 12, 2026.Net sales for the second quarter of 2026 are expected to be in excess of...

SEATTLE--(BUSINESS WIRE)--Compvide, Inc., il pioniere biotech dell'intelligence dei complementi funzionali tramite la diagnostica innovativa e il monitoraggio della risposta immunitaria, oggi ha dato il via a una collaborazione strategica con OpZira, Inc. per supportare la crescita continuativa dell'azienda e velocizzare lo sviluppo di CIMED, la sua piattaforma proprietaria. "Grazie a questa collaborazione, OpZira sarà in grado di proporre un supporto operativo completo per le attività cliniche...

SEATTLE--(BUSINESS WIRE)--Compvide, Inc., société de biotechnologie pionnière dans le domaine de l’intelligence fonctionnelle du système du complément grâce à des outils diagnostiques innovants et au suivi de la réponse immunitaire, a annoncé aujourd’hui un partenariat stratégique avec OpZira, Inc. afin de soutenir sa croissance et d’accélérer le développement de sa plateforme propriétaire CIMED. « Dans le cadre de ce partenariat, OpZira fournira un soutien opérationnel complet dans les domaine...

SEATTLE--(BUSINESS WIRE)--Compvide Inc., ein Biotechnologieunternehmen, das durch innovative Diagnostik und die Überwachung von Immunreaktionen Pionierarbeit im Bereich der funktionellen Komplement-Intelligenz leistet, gab heute eine strategische Zusammenarbeit mit OpZira Inc. bekannt. Ziel ist die Förderung des Unternehmenswachstums sowie die Entwicklung der firmeneigenen CIMED-Plattform. „Im Rahmen dieser Zusammenarbeit wird OpZira umfassende operative Unterstützung in den Bereichen Klinik, K...

SEATTLE--(BUSINESS WIRE)--Compvide, Inc., een biotechnologiebedrijf dat baanbrekend werk verricht op het gebied van functionele complementintelligentie door middel van innovatieve diagnostiek en monitoring van immuunreacties, heeft vandaag een strategische samenwerking met OpZira, Inc. aangekondigd. Deze is bedoeld om de verdere groei van het bedrijf te ondersteunen en de ontwikkeling van zijn eigen CIMED-platform te versnellen. "Door deze samenwerking gaat OpZira uitgebreide operationele onder...

SEATTLE--(BUSINESS WIRE)--Compvide, Inc., una empresa de biotecnología pionera en el campo de la inteligencia del complemento funcional mediante diagnósticos innovadores y la monitorización de la respuesta inmunitaria, ha anunciado hoy una colaboración estratégica con OpZira, Inc. con el fin de garantizar el crecimiento continuo de la empresa y acelerar el desarrollo de su plataforma patentada CIMED. «Gracias a esta colaboración, OpZira proporcionará un servicio integral de apoyo operativo en l...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of the EyeGility™ Inserter preloaded IOL delivery system. “The enVista IOL platform has long been appreciated by surgeons for its glistening-free optic and differentiated optic portfolio to suit a wide range of patients,” said Wayne Caulder, vice president and general manager, North America Surgi...